|Articles|November 9, 2015
Parexel Expands Market Access, Clinical Evidence Services
Parexel announces PAREXEL® Access, a service that is directed toward clients’ market access and ongoing commercial success.
Advertisement
Parexel announces PAREXEL® Access, a service that is directed toward clients’ market access and ongoing commercial success. PAREXEL Access combines the expertise of HERON™ Commercialization , QSI’s pharmacovigilance , PAREXEL Medical Communications, and PAREXEL Peri-/Post-approval services, which focuses on clinical research and operations, market access consulting, medical communications, and pharmacovigilance to help companies identify, evaluate, generate and communicate the evidence of its product.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
2
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
3
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
4
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
5